Key facts
- This page summarizes GNI Group Ltd.'s Form 4 filing for GYRE THERAPEUTICS, INC. (GYRE).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 22 Nov 2023, 19:27.
GNI Group Ltd. - 30 Oct 2023 Form 4 Insider Report for GYRE THERAPEUTICS, INC. (GYRE)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- GYRE
- Reported as of
- 30 Oct 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Nov 2023, 19:27:22 UTC
- Prior SEC filing
- 31 Oct 2023
- Next SEC filing
- 06 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Branden Berns, as attorney-in-fact for GNI Group Ltd.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
GNI Group Ltd. filed Form 4 for GYRE THERAPEUTICS, INC. (GYRE) on 22 Nov 2023.
Change
- Previous filing in this sequence was filed on 31 Oct 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GYRE
transaction
Common Stock
Other
- Transaction value
- Shares
- +63,588,119
- Change %
- +15221%
- Price
- Shares after
- 64,005,887
- Date
- 30 Oct 2023
- Ownership
- See Remarks
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents the number of shares of common stock of the Issuer received by the Reporting Person in exchange for the shares of Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares ("CPI") and Further Challenger International Limited, a company incorporated and existing under the laws of the British Virgin Islands with company number 1982271, held by the Reporting Person pursuant to that certain Business Combination Agreement, dated as of December 26, 2022 and as amended on March 29, 2023 and August 30, 2023 (the "Business Combination Agreement"), by and among Catalyst Biosciences, Inc., a Delaware corporation,
Footnote F2
[cont'd from FN 1] GNI USA, Inc., a Delaware corporation ("GNI USA"), the Reporting Person, GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability, Shanghai Genomics, Inc., a company organized under the laws of the People's Republic of China, the Minority Holders (as defined therein) and CPI. Pursuant to the terms of the Business Combination Agreement, on October 30, 2023, the Issuer acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China.
Footnote F3
These securities are held by GNI USA which is a wholly-owned subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability ("GNI Japan"). GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI USA.